RGNX
Regenxbio Inc

2,546
Mkt Cap
$553.31M
Volume
444,967.00
52W High
$13.93
52W Low
$5.04
PE Ratio
-3.13
RGNX Fundamentals
Price
$10.87
Prev Close
$10.93
Open
$11.18
50D MA
$11.07
Beta
1.61
Avg. Volume
608,908.61
EPS (Annual)
-$4.59
P/B
3.43
Rev/Employee
$236,056.66
Loading...
Loading...
News
all
press releases
Savant Capital LLC Invests $226,000 in REGENXBIO Inc. $RGNX
Savant Capital LLC purchased a new position in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm...
MarketBeat·14h ago
News Placeholder
More News
News Placeholder
REGENXBIO (NASDAQ:RGNX) Cut to "Sell" at Wall Street Zen
Wall Street Zen cut shares of REGENXBIO from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat·5d ago
News Placeholder
Los Angeles Capital Management LLC Makes New Investment in REGENXBIO Inc. $RGNX
Los Angeles Capital Management LLC bought a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and...
MarketBeat·6d ago
News Placeholder
REGENXBIO (NASDAQ:RGNX) Posts Earnings Results, Beats Expectations By $0.18 EPS
REGENXBIO (NASDAQ:RGNX - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($1.20) EPS for the quarter, beating analysts' consensus estimates of...
MarketBeat·12d ago
News Placeholder
REGENXBIO (NASDAQ:RGNX) Price Target Raised to $19.00
Royal Bank Of Canada upped their price target on REGENXBIO from $17.00 to $19.00 and gave the stock an "outperform" rating in a report on Friday...
MarketBeat·12d ago
News Placeholder
Regenxbio (RGNX) Reports Q3 Loss, Beats Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of +13.04% and +23.73%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial...
PR Newswire·22d ago
News Placeholder
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter...
PR Newswire·23d ago
News Placeholder
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., Oct. 15, 2025 ROCKVILLE, Md., Oct. 15, 2025...
PR Newswire·1mo ago
News Placeholder
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting PR Newswire...
PR Newswire·1mo ago

Latest RGNX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.